Abstract
GEN EdgeVol. 4, No. 1 Cell CultureXilis' Precision Oncology Platform Guides Treatment and Drug DiscoveryThe success of the biotechnology company's MicroOrganoSphere (MOS) technology has yielded a series A extension, bringing the round total to more than $89 million.Jonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:13 Jul 2022https://doi.org/10.1089/genedge.4.1.83AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 4Issue 1Jan 2022 Information© 2022 by GEN PublishingTo cite this article:Jonathan D Grinstein.Xilis' Precision Oncology Platform Guides Treatment and Drug Discovery.GEN Edge.Jan 2022.502-505.http://doi.org/10.1089/genedge.4.1.83Published in Volume: 4 Issue 1: July 13, 2022PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
